J Korean Pediatr Soc.
2001 Jan;44(1):32-39.
A Comparative Study of the Effects of Intravenous Indomethacin and Oral Mefenamic Acid in the Treatment of Premature Infants with Patent Ductus Arteriosus
- Affiliations
-
- 1Department of Pediatrics, College of Medicine, Hanyang University, Seoul, Korea.
- 2Department of Thoracic Surgery, College of Medicine, Hanyang University, Seoul, Korea.
Abstract
-
PURPOSE: For the management of patent ductus arteriosus(PDA) in premature infants, fluid restriction, correction of anemia, mechanical ventilation, diuretics, and surgery have been used, and the closure rate of PDA has improved significantly since the introduction of indomethacin and mefenamic acid as pharmacologic treatments of PDA. We studied to evaluate and compare the therapeutic effects of indomethacin and mefenamic acid in the management of premature infants with PDA.
METHODS
32 inborn premature infants who were hospitalized in NICU and diagnosed as PDA by cardiac sector were retrospectively studied and divided into two groups : An indomethacin treated group and a mefenamic acid treated group. Their gestational age, birth weight, blood urea nitrogen(BUN), creatinine(Cr), platelet count, urine output, fluid therapy, postnatal age, closure rate of PDA, and etc. were examined and conpared through the medical record review.
RESULTS
The mean postnatal age on drug use was 4.6 days in intravenous indomethacin treated group(n=18), 9.0 days in oral mefenamic acid treated group(n=14), and the mean gestational age was 32.0 weeks and 32.3 weeks, respectively. After the use of each drugs, platelet count and urine output decreased, whereas blood urea nitrogen and creatinine increased. The closure rate of PDA was 94.4%(17/18) in the indomethacin treated group and 85.7%(12/14) in the mefenamic acid treated group(P=0.568). On the multivariate analysis except for the drugs, the most significant factor on PDA closure in preterm neonates was total amount of intake(P=0.000).
CONCLUSION
We conclude that intravenous indomethacin is as effective as oral mefenamic acid in the therapy of preterm infants with PDA.